-
公开(公告)号：US20240043527A1
公开(公告)日：2024-02-08
申请号：US17915567
申请日：2021-03-29
Applicant: BioNTech SE
Inventor： Ugur Sahin , Claudia Lindemann , Jan Diekmann , Kerstin Brettschneider , Hayat Bähr-Mahmud , Ursula Ellinghaus , Leyla Fischer , Christiane Stadler , Özlem Türeci
CPC classification number: C07K16/28 , A61P35/00 , C07K2317/522 , C07K2317/14
Abstract: The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).
-
公开(公告)号：US20240000921A1
公开(公告)日：2024-01-04
申请号：US18341590
申请日：2023-06-26
Applicant: BioNTech SE
Inventor： Alexander Muik , Asaf Poran , Kena Anne Swanson , Qi Yang , Hui Cai , Ugur Sahin , Kayvon Modjarrad
IPC: A61K39/215 , C07K14/005
CPC classification number: A61K39/215 , A61K2039/53 , C07K14/005
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
-
公开(公告)号：US20230265454A1
公开(公告)日：2023-08-24
申请号：US18007550
申请日：2021-06-01
Applicant: BioNTech SE , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenber-Universitä Mainz
Inventor： Mario Perkovic , Sonja Witzel , Tim Beissert , Ugur Sahin
IPC: C12N15/86 , C12N15/113
CPC classification number: C12N15/86 , C12N15/113 , C12N2770/36143
Abstract: The present invention embraces an RNA replicon (self-amplifying RNA vector (saRNA)) that can be replicated by a replicase of a self-replicating virus, e.g., a replicase of alphavirus origin. According to the invention, translation of the replicase open reading frame is uncoupled from a 5′-terminal cap by placing translation of the replicase open reading frame under the translational control of an internal ribosome entry site (IRES). Thereby the initiation of translation depends on the molecular properties of the respective IRES, which compared to cap-dependent translation may require less or no cellular initiation factors to direct the ribosome to the translational start site. According to the invention, IRES-controlled replicase translation may allow the use of uncapped synthetic saRNA. Furthermore, the use of an IRES provides for the option to insert additional transgenes upstream to the IRES.
-
公开(公告)号：US11701413B2
公开(公告)日：2023-07-18
申请号：US16500005
申请日：2018-04-10
Applicant: BioNTech SE , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
Inventor： Ugur Sahin , Sebastian Kreiter , Christina Krienke , Jutta Petschenka , Lena Mareen Kranz , Mustafa Diken
IPC: A61K39/00 , A61P37/06 , C12N15/11 , C12N15/117
CPC classification number: A61K39/0008 , A61P37/06 , C12N15/11 , C12N15/117 , A61K2039/53 , A61K2039/55555 , C12N2310/335
Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.
-
公开(公告)号：US11673939B2
公开(公告)日：2023-06-13
申请号：US16972794
申请日：2019-06-06
Applicant: BioNTech SE
Inventor： Ugur Sahin , Bonny Gaby Lui , Nadja Salomon , Joycelyn Wüstehube-Lausch , Matin Daneschdar , Hans-Ulrich Schmoldt , Markus Fiedler
IPC: C07K14/78 , C07K1/107 , G01N33/574 , G01N33/68 , A61K38/00
CPC classification number: C07K14/78 , C07K1/1075 , G01N33/574 , G01N33/68 , A61K38/00
Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.
-
Patent Agency Ranking
公开(公告)号：US20230073461A1
公开(公告)日：2023-03-09
申请号：US17699035
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K39/12 , A61K31/7105 , A61K31/7115 , A61K31/712 , A61K9/127 , A61K9/51 , A61P31/14 , B82Y5/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US11547673B1
公开(公告)日：2023-01-10
申请号：US17233396
申请日：2021-04-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20220378876A1
公开(公告)日：2022-12-01
申请号：US17763329
申请日：2020-09-22
Applicant: BioNTech SE , Tron-Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz
Inventor： Ugur Sahin , Mathias Vormehr , Jan David Beck , Mustafa Diken , Sebastian Kreiter
IPC: A61K38/20 , A61K39/39 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: Tumor cells often evade an immune response, e.g., by reducing or eliminating MHC expression and/or IFN-signaling, which enables uncontrolled growth. We demonstrate herein that antibody-based immunotherapy in combination with IL2 administration is an effective therapy against such resistant tumors. Specifically, the present disclosure relates to methods of treating a subject with cancer that is at least partially resistant to an MHC-dependent T cell response comprising administering to the subject: a. a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof; and b. antibody-based immunotherapy.
-
公开(公告)号：US11504419B2
公开(公告)日：2022-11-22
申请号：US16172063
申请日：2018-10-26
Applicant: BioNTech SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
Inventor： Ugur Sahin , Claudia Paret , Kirsten Vormbrock , Christian Bender , Jan Diekmann
Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
-
公开(公告)号：US20220257783A1
公开(公告)日：2022-08-18
申请号：US17688707
申请日：2022-03-07
Applicant: BioNTech SE
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
-
-
-
-
-
-
-
-
-
Search Results
83
records
(took 0.027 seconds)
